NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United ...
On February 25, 2025, the U.S. Centers for disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or ...
Shares of Valneva SE (NASDAQ:VALN – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $6.86, but opened at $7.11. Valneva shares last traded at $ ...
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...
Valneva SE (NASDAQ:VALN – Free Report) – Stock analysts at HC Wainwright lowered their Q4 2024 EPS estimates for shares of Valneva in a report issued on Wednesday, February 19th.HC Wainwright ...
Stay informed and make well-considered decisions with our Ratings Table. Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
This page features the latest news about the Valneva SE stock. H.C. Wainwright cuts Valneva stock target to $17, maintains Buy On Tuesday, H.C. Wainwright analyst Edward White adjusted the price ...
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...